Novavax Succeeds In Phase III Flu Vaccine Trial Against Sanofi’s Fluzone
Executive Summary
Phase III trial could lead to mid-2020 BLA filing to prevent seasonal influenza in adults 65 and older. Novavax also talked up the potential value of its adjuvant in COVID-19 vaccine development.
You may also be interested in...
Novavax Push For COVID-19 Vaccine Manufacturing Capacity Delays Flu Vaccine Application
As CEO Erck touts that its COVID vaccine has the 'best data,' Novavax prepares to enter Phase III trials and inks deal with Serum Institute to boost production even as its 'almost a perfect flu vaccine' remains on hold.
Coronavirus Update: Novavax's $384m Is CEPI’s Biggest Vaccine Funding
Pioneer of nanoparticle vaccine technology is latest to get financial backing from the foundation.
Coronavirus Update: FDA Fast-Tracks Blood Plasma Trials, Novavax Closes In On Vaccine Start
As US cases set to reach half a million, FDA gives green light to blood plasma trials to help meet urgent need for therapies.